Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris

ClinicalTrials.gov ID: NCT03915860

Public ClinicalTrials.gov record NCT03915860. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center Study to Evaluate Subject Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Participant Reported Outcomes with use of Trifarotene 50 μg/g Cream in participants with Moderate Facial and Truncal Acne Vulgaris

Study identification

NCT ID
NCT03915860
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Galderma R&D
Industry
Enrollment
47 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
9 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 27, 2019 (Actual)
Primary completion
Dec 23, 2019 (Actual)
Completion
Dec 23, 2019 (Actual)
Last update posted
Dec 15, 2021

2019

United States locations

U.S. sites
9
U.S. states
5
U.S. cities
9
Facility City State ZIP Site status
Galderma Investigational Site Fort Smith Arkansas 72916 —
Galderma Investigational Site Beverly Massachusetts 01915 —
Galderma Investigational Site Portsmouth New Hampshire 03801 —
Galderma Investigational Site Philadelphia Pennsylvania 19103 —
Galderma Investigational Site Austin Texas 78759 —
Galderma Investigational Site Beaumont Texas 77701 —
Galderma Investigational Site Irving Texas 75062 —
Galderma Investigational Site Pflugerville Texas 78660 —
Galderma Investigational Site Richardson Texas 75081 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03915860, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 15, 2021 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03915860 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →